Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium

Int J Clin Pharm. 2016 Apr;38(2):310-20. doi: 10.1007/s11096-015-0242-9. Epub 2016 Jan 9.

Abstract

Background: Many drugs, including haloperidol, are linked with a risk of QTc-prolongation, which can lead to Torsade de Pointes and sudden cardiac death.

Objective: To investigate the prevalence of concomitant risk factors for QTc-prolongation in patients treated with haloperidol, and the use of safety measures to minimize this risk.

Setting: University Hospitals of Leuven, Belgium. Methods A retrospective epidemiological study was performed. On 15 consecutive Mondays, all patients with a prescription for haloperidol were included. A risk score for QTc-prolongation, inspired by the pro-QTc score of Haugaa et al., was calculated based on gender, comorbidities, lab results and concomitant QTc-prolonging drugs (each factor counting for one point). Available electrocardiograms before and during the treatment of haloperidol were registered.

Main outcome measure: Management of the risk of QTc-prolongation.

Results: Two hundred twenty-two patients were included (59.0 % men, median age 77 years) of whom 26.6 % had a risk score of ≥4 (known to significantly increase the mortality). Overall, 24.3 % received haloperidol in combination with other drugs with a known risk of Torsade de Pointes. Half of the patients had an electrocardiogram in the week before the start of haloperidol; only in one-third a follow-up electrocardiogram during haloperidol treatment was performed. Of the patients with a moderately (n = 41) or severely (n = 14) prolonged QTc-interval before haloperidol, 48.8 % and 42.9 % respectively had a follow-up electrocardiogram. In patients with a risk score ≥4, significantly more electrocardiograms were taken before starting haloperidol (p = 0.020).

Conclusions: Although many patients had risk factors for QTc-prolongation (including the use of other QTc-prolonging drugs) or had a prolonged QTc on a baseline electrocardiogram, follow-up safety measures were limited. Persistent efforts should be taken to develop decision support systems to manage this risk.

Keywords: Haloperidol; QTc-prolongation; Risk management; Sudden cardiac death; Torsade de Pointes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antipsychotic Agents / adverse effects*
  • Belgium / epidemiology
  • Electrocardiography / drug effects
  • Follow-Up Studies
  • Haloperidol / adverse effects*
  • Hospitals, University* / statistics & numerical data
  • Humans
  • Long QT Syndrome / chemically induced*
  • Long QT Syndrome / diagnosis
  • Long QT Syndrome / epidemiology*
  • Middle Aged
  • Risk Management / methods*
  • Risk Management / standards
  • Torsades de Pointes / chemically induced
  • Torsades de Pointes / diagnosis
  • Torsades de Pointes / epidemiology
  • Young Adult

Substances

  • Antipsychotic Agents
  • Haloperidol